Cargando…

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers

BACKGROUND: Several countries have used pegylation technology to improve the pharmacokinetic properties of essential drugs. Recently, a novel interferon alfa-2b protein conjugated to four-branched 12 kDa polyethylene glycol molecules was developed jointly between Cuba and Brazil. The aim of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa, Marisa Boff, Picon, Paulo Dornelles, Sander, Guilherme Becker, Cuni, Hugo Nodarse, Silva, Carmen Valenzuela, Meireles, Rolando Páez, Góes, Ana Carolina Magalhães Andrade, Batoreu, Nadia Maria, Maia, Maria de Lourdes de Sousa, Albuquerque, Elizabeth Maciel, Matos, Denise Cristina de Souza, Saura, Pedro Lopez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755306/ https://www.ncbi.nlm.nih.gov/pubmed/29301580 http://dx.doi.org/10.1186/s40360-017-0192-z

Ejemplares similares

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study
por: García-García, Idrian, et al.
Publicado: (2010)

Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha
por: da Silva, Andréa Marques Vieira, et al.
Publicado: (2021)

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil
por: Artico, Simara, et al.
Publicado: (2012)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial
por: Picon, Paulo Dornelles, et al.
Publicado: (2013)

Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
por: Mata-Marín, JA, et al.
Publicado: (2010)

Extensive Psoriasis Induced by Pegylated Interferon Alfa-2a and Ribavirin in the Treatment of Chronic Hepatitis C
por: Kim, Gun-Wook, et al.
Publicado: (2013)

Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
por: Aghemo, Alessio, et al.
Publicado: (2011)

Breastfeeding in patients with Gaucher disease: Is taliglucerase alfa safe?
por: Paskulin, Livia, et al.
Publicado: (2019)

Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study
por: de Menezes Martins, Reinaldo, et al.
Publicado: (2018)

Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin
por: Choi, Sang Bun, et al.
Publicado: (2011)

Transient Visual Loss in a Hepatitis C Patient Treated With Pegylated Interferon Alfa-2a and Ribavirin
por: Jancoriene, Ligita, et al.
Publicado: (2014)

Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study
por: Mahdavi, Meisam, et al.
Publicado: (2013)

Lichen Planus Induced by Pegylated Interferon Alfa-2a Therapy in a Patient Monitored for Delta Hepatitis
por: Kaya, Safak, et al.
Publicado: (2015)

Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C
por: Alkan, Erhan, et al.
Publicado: (2016)

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
por: Jia, Dong-Dong, et al.
Publicado: (2021)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis
por: Wagner, Frank, et al.
Publicado: (2023)

Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response
por: Etoh, Reiko, et al.
Publicado: (2011)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
por: Ma, Hui, et al.
Publicado: (2016)

Early optic neuropathy during pegylated alfa 2-B interferon and ribavirin HCV treatment. A case report
por: Chis, Bogdan Augustin, et al.
Publicado: (2019)

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
por: Huang, Yi-Wen, et al.
Publicado: (2020)

PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system
por: Castillo, Paula M, et al.
Publicado: (2014)

Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure
por: Weng, Min, et al.
Publicado: (2013)

The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir
por: Wei, Xin, et al.
Publicado: (2016)

Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety
por: Stidl, Reinhard, et al.
Publicado: (2018)

The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin
por: Szymanek-Pasternak, Anna, et al.
Publicado: (2016)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
por: He, Jingjing, et al.
Publicado: (2023)

ALFA
por: Hiller, Karlheinz
Publicado: (2012)

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
por: Okikiolu, Jumoke, et al.
Publicado: (2022)

Conventional and PEGylated Liposomes as Vehicles of Copaifera sabulicola
por: Blanco, Ian M. R., et al.
Publicado: (2023)

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial
por: Mecenate, Fabrizio, et al.
Publicado: (2010)

Symptomatic Acute Hepatitis C in Egypt: Diagnosis, Spontaneous Viral Clearance, and Delayed Treatment with 12 Weeks of Pegylated Interferon Alfa-2a
por: Sharaf Eldin, Noha, et al.
Publicado: (2008)

Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2
por: Taura, Naota, et al.
Publicado: (2012)

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study
por: Pandit, Anuja, et al.
Publicado: (2021)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
por: Levent, Görenek, et al.
Publicado: (2006)

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
por: Mascarenhas, J, et al.
Publicado: (2019)

PEGylation of the antimicrobial peptide LyeTx I-b maintains structure-related biological properties and improves selectivity
por: Moreira Brito, Júlio César, et al.
Publicado: (2022)

ALFA - Absolute Luminosity measurement For Atlas alias ALFA in ATLAS
por: Sykora, Tomas
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ol80aqeisc44n2vlftckj4qha1